Association between genetically proxied PCSK9 inhibition and prostate cancer risk: A Mendelian randomisation study

BACKGROUND: Prostate cancer (PrCa) is the second most prevalent malignancy in men worldwide. Observational studies have linked the use of low-density lipoprotein cholesterol (LDL-c) lowering therapies with reduced risk of PrCa, which may potentially be attributable to confounding factors. In this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Si, Yarmolinsky, James, Gill, Dipender, Bull, Caroline J., Perks, Claire M., Davey Smith, George, Gaunt, Tom R., Richardson, Tom G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810198/
https://www.ncbi.nlm.nih.gov/pubmed/36595504
http://dx.doi.org/10.1371/journal.pmed.1003988

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9810198/
https://www.ncbi.nlm.nih.gov/pubmed/36595504
http://dx.doi.org/10.1371/journal.pmed.1003988

Ejemplares similares